macro

FDA Rejects Capricor's Deramiocel Application, Citing Weak Evidence

FDA issued a Complete Response Letter on Capricor's resubmitted Deramiocel filing, citing weak evidence of effectiveness and other clinical gaps.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

The US Food and Drug Administration has issued a Complete Response Letter on Capricor Therapeutics' resubmitted filing for Deramiocel. The agency pointed to insufficient evidence of effectiveness and other clinical shortcomings, according to TradingView, which cites GlobeNewswire.

The company said it held about $198.5 million in cash and securities as of September 30, 2026, enough, in its view, to fund at least 12 months of planned operations. Capricor is reviewing the letter and will determine its next regulatory steps. The release does not specify the deficiencies, so the scope of any required work remains unclear. The company is also reviewing operating costs to extend its runway.

why it matters

For Capricor shares this is a major setback, since approval of its lead candidate is now blocked. The next key event will be the company's assessment of the letter and its disclosure of specific regulatory steps. Investors will watch the time and money needed to address the FDA's concerns.

market impact

Акции Capricor: отказ FDA блокирует одобрение ведущего препарата — давление на бумаги

  • Capricor shares (CAPR) pressure down — a rejection by the FDA blocks approval of the lead candidate

tags

instruments

CAPRАкции CapricorCapricor Therapeutics

on polymarket

sources

  1. Capricor Therapeutics (CAPR) Receives FDA Rejection of Deramiocel Application — TradingView, 21 November 2026 at 00:55 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗